

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7185294

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	SPARCBIO LLC	10/26/2021
RECEIVING PARTY DATA		
Name:	GIRAFPHARMA LLC	
Street Address:	P.O. BOX 318009	
City:	SAN FRANCISCO	
State/Country:	CALIFORNIA	
Postal Code:	94131-9991	
PROPERTY NUMBERS Total: 3		
Property Type	Number	
Application Number:	16746769	
PCT Number:	US2020014208	
Application Number:	17675494	
CORRESPONDENCE DATA		
Fax Number:	(650)494-0792	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	617-648-4782	
Email:	mchacon@mofo.com	
Correspondent Name:	MARK D. MCBRIAR	
Address Line 1:	MORRISON & FOERSTER LLP	
Address Line 2:	200 CLARENDON STREET, 21ST FLOOR	
Address Line 4:	BOSTON, MASSACHUSETTS 02116	
ATTORNEY DOCKET NUMBER:	19369-20009.00, .01, .40	
NAME OF SUBMITTER:	MARK D. MCBRIAR	
SIGNATURE:	/Mark D. McBriar/	
DATE SIGNED:	02/18/2022	
Total Attachments: 2		
source=19369-20009.00 + .40 4 - SPARCBIO_LLC to Girafpharma_Assignment - EXECUTED#page1.tif		
source=19369-20009.00 + .40 4 - SPARCBIO_LLC to Girafpharma_Assignment - EXECUTED#page2.tif		

ENTITY TO ENTITY ASSIGNMENT

This Assignment is by:

Assignor: SPARCBIO LLC
Address: P.O. Box 318009, San Francisco, California 94131-9991, United States of America
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignor"), which is the sole and exclusive owner, by assignment, of the U.S. patent application identified below:

Serial No.: 16/746,769 Filing Date: January 17, 2020
Serial No.: PCT/US2020/014208 Filing Date: January 17, 2020
Title: 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF

This Assignment is to:

Assignee: GIRAFPHARMA LLC
Address: P.O. Box 318009, San Francisco, California 94131-9991, United States of America
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patent application and the inventions covered thereby.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, and any and all non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.
2. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.
3. Assignor hereby grants Assignee's attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.
6. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.


sf-4173359

Attorney Docket No.: 19369-20009.00 and 19369-20009.40
Client Reference No.: NUVF-00009-US and NUVF-00009-PCT

In witness whereof, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:


Date: 10/20/2021

Signature: 

Name: Sarvajit Chakravarty
Title: CEO and President
Company: SPARCBIO LLC

ASSIGNEE:

Date: 12/3/2021

Signature: 

Name: Vandana Date
Title: Chairman & Chief Strategy Officer
Company: GIRAFPHARMA LLC

sf-4173359